Loading provider…
- Featuresarrow_drop_down
- Solutionsarrow_drop_down
Loading provider…
Your Medical Sales Assistants that help you easily find, convert and close your ideal providersNeurology Physician in Burlington, VT
NPI: 1255575726Primary Practice Location
University of Vermont Medical Center Inc
111 Colchester Ave, Burlington, VT
Primary Employer
Uvm Medical Center
uvmhealth.org
HQ Phone
Get M.D. Alissa's Phone NumberMobile
Get M.D. Alissa's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardVT State Medical License
The Warren Alpert Medical School of Brown University
medical.brown.edu
Medical School
Until 2009
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 63 | 137 |
| 2 | 99231Subsequent hospital inpatient care, typically 15 minutes per day | 46 | 110 |
| 3 | 99214Established patient office or other outpatient visit, 30-39 minutes | 45 | 63 |
| 4 | 99222Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 35 | 36 |
| 5 | 99232Subsequent hospital inpatient care, typically 25 minutes per day | 12 | 16 |
Authors: Thomas, Alissa A, Preston, Julie, Scott, Rod C, Bujarski, Krzysztof A
Journal: Epilepsy Behav
Publication Date: 2013-09-08
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: DRUG: Temozolomide, OTHER: Laboratory Biomarker Analysis, OTHER: Quality-of-Life Assessment, DRUG: Veliparib, OTHER: Placebo Administration
Lead Sponsor: National Cancer Institute (NCI)
Collaborators: NRG Oncology
Intervention / Treatment: OTHER: Questionnaire Administration, BIOLOGICAL: Nivolumab, DRUG: Temozolomide, BIOLOGICAL: Ipilimumab, OTHER: Quality-of-Life Assessment, RADIATION: Radiation Therapy, PROCEDURE: Contrast-enhanced Magnetic Resonance Imaging, DEVICE: NovoTTF-100A Device
Lead Sponsor: Alliance for Clinical Trials in Oncology
Collaborators: Genentech, Inc., National Cancer Institute (NCI), GlaxoSmithKline, Brain Science Foundation
Intervention / Treatment: DRUG: Abemaciclib, DRUG: Vismodegib, DRUG: Capivasertib, DRUG: FAK Inhibitor GSK2256098
